Jasmin Islam

Jasmin Islam

Auto-generated profile, based on publicly available information

Jasmin Islam

UK Health Security Agency

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2017 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
ASAnna C. Seale
Anna C. Seale
NGN. Claire Gordon
N. Claire Gordon
JIJasmin Islam
Jasmin Islam
SPSharon J. Peacock
Sharon J. Peacock
JSJ. Anthony G. Scott
J. Anthony G. Scott
Drug-resistant infections caused by bacteria with increasing antimicrobial resistance (AMR) threaten our ability to treat life-threatening conditions. Tackling AMR requires international collaboration and partnership. An early and leading priority to do this is to strengthen AMR surveillance, particularly in low-income countries where the burden of infectious diseases is highest and where data are most limited. The World Health Organization (WHO) has developed the Global AMR Surveillance System (GLASS) as one of a number of measures designed to tackle the problem of AMR, and WHO member states have been encouraged to produce National Action Plans for AMR by 2017. However, low-income countries are unlikely to have the resources or capacity to implement all the components in the GLASS manual. To facilitate their efforts, we developed a guideline that is aligned to the GLASS procedures, but written specifically for implementation in low-income countries. The guideline allows for flexibility across different systems, but has sufficient standardisation of core protocols to ensure that, if followed, data will be valid and comparable. This will ensure that the surveillance programme can provide health intelligence data to inform evidence-based interventions at local, national and international levels.

1 March 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JFJ.M. Fitzpatrick
J.M. Fitzpatrick
JBJ.S. Biswas
J.S. Biswas
JEJ.D. Edgeworth
J.D. Edgeworth
JIJ. Islam
J. Islam
ALA.J. Lavery
A.J. Lavery
ENEmmanuel Nsutebu
Emmanuel Nsutebu

1 May 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
VSV.A. Schweitzer
V.A. Schweitzer
IHI. van Heijl
I. van Heijl
CWC.H. van Werkhoven
C.H. van Werkhoven
JIJ. Islam
J. Islam
KHK.D. Hendriks-Spoor
K.D. Hendriks-Spoor
MWM. Wolkewitz
M. Wolkewitz

27 September 2024 in Journal of Infection
Verified
Journal Article
Open access
PKPeter D. Kirwan
Peter D. Kirwan
SFSarah Foulkes
Sarah Foulkes
KMKatie Munro
Katie Munro
DSDominic Sparkes
Dominic Sparkes
JSJasleen Kaur Kaur Daljit Daljit Singh
Jasleen Kaur Kaur Daljit Daljit Singh
SHSusan Hopkins
Susan Hopkins
Bivalent original/BA.4-5 and monovalent XBB.1.5 mRNA boosters were offered to UK healthcare workers (HCWs) in autumn 2023. We aimed to estimate booster vaccine effectiveness (VE) and post-infection immunity among the SIREN HCW cohort over the subsequent 6-month period of XBB.1.5 and JN.1 variant circulation. Between October 2023 to March 2024, 2,867 SIREN study participants tested fortnightly for SARS-CoV-2 and completed symptoms questionnaires. We used multi-state models, adjusted for vaccination, prior infection, and demographic covariates, to estimate protection against mild/asymptomatic and moderate SARS-CoV-2 infection. Half of participants (1,422) received a booster during October 2023 (280 bivalent, 1,142 monovalent), and 536 (19%) had a PCR-confirmed infection over the study period. Bivalent booster VE was 15.1% (-55.4 to 53.6%) at 0-2 months and 4.2% (-46.4 to 37.3%) at 2-4 months post-vaccination. Monovalent booster VE was 44.2% (95% CI 21.7 to 60.3%) at 0-2 months, and 24.1% (-0.7 to 42.9%) at 2-4 months. VE was greater against moderate infection than against mild/asymptomatic infection, but neither booster showed evidence of protection after 4 months. Controlling for vaccination, compared to an infection >2 years prior, infection within the past 6 months was associated with 58.6% (30.3 to 75.4%) increased protection against moderate infection, and 38.5% (5.8 to 59.8%) increased protection against mild/asymptomatic infection. Monovalent XBB.1.5 boosters provided short-term protection against SARS-CoV-2 infection, particularly against moderate symptoms. Vaccine formulations which target the circulating variant may be suitable for inclusion in seasonal vaccination campaigns among HCWs.

28 February 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JIJ Islam
J Islam
Diane Ashiru-OredopeDiane Ashiru-Oredope
Diane Ashiru-Oredope
EBEmma L Budd
Emma L Budd
PHPhilip Howard
Philip Howard
AWA S Walker
A S Walker
MLM J Llewelyn
M J Llewelyn
In 2016/2017, a financially linked antibiotic prescribing quality improvement initiative Commissioning for Quality and Innovation (AMR-CQUIN) was introduced across acute hospitals in England. This aimed for >1% reductions in DDDs/1000 admissions of total antibiotics, piperacillin/tazobactam and carbapenems compared with 2013/2014 and improved review of empirical antibiotic prescriptions. To assess perceptions of staff leading antimicrobial stewardship activity regarding the AMR-CQUIN, the investments made by hospitals to achieve it and how these related to achieving reductions in antibiotic use. We invited antimicrobial stewardship leads at acute hospitals across England to complete a web-based survey. Antibiotic prescribing data were downloaded from the PHE Antimicrobial Resistance Local Indicators resource. Responses were received from 116/155 (75%) acute hospitals. Owing to yearly increases in antibiotic use, most trusts needed to make >5% reductions in antibiotic consumption to achieve the AMR-CQUIN goal of 1% reduction. Additional funding was made available at 23/113 (20%) trusts and, in 18 (78%), this was <10% of the AMR-CQUIN value. Nationally, the annual trend for increased antibiotic use reversed in 2016/2017. In 2014/2015, year-on-year changes were +3.7% (IQR −0.8%, +8.4%), +9.4% (+0.2%, +19.5%) and +5.8% (−6.2%, +18.2%) for total antibiotics, piperacillin/tazobactam and carbapenems, respectively, and +0.1% (−5.4%, +4.0%), −4.8% (−16.9%, +3.2%) and −8.0% (−20.2%, +4.0%) in 2016/2017. Hospitals where staff believed they could reduce antibiotic use were more likely to do so (P < 0.001). Introducing the AMR-CQUIN was associated with a reduction in antibiotic use. For individual hospitals, achieving the AMR-CQUIN was associated with favourable perceptions of staff and not availability of funding.

1 June 2014 in Anaerobe
Verified
Journal Article
Closed access
JIJ. Islam
J. Islam
ATA.L. Taylor
A.L. Taylor
KRK. Rao
K. Rao
GHG. Huffnagle
G. Huffnagle
VYV.B. Young
V.B. Young
MLM.J. Llewelyn
M.J. Llewelyn